Non-Alcoholic Fatty Liver Disease (NAFLD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Non-Alcoholic Fatty Liver Disease (NAFLD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Summary

This reports provides a data-driven overview of the current and future competitive landscape in NAFLD therapeutics.

Synopsis

  • In 2022, there will be more than 1.3 billion total prevalent cases of NAFLD across 16 pharmaceutical markets.
  • Currently, there are no FDA or EMA approved drugs for NAFLD.
  • The NAFLD pipeline consists of 145 pharmaceuticals spanning all stages of development, with four drugs in late-stage development.
  • Non-commercial sponsors dominate clinical trial development in NAFLD.
  • Deals involving partnerships and acquisitions were the most common type of deals globally.
  • One innovator product (resmetirom) is expected to be approved within the next 18 months.
Scope

GlobalData’s Non-Alcoholic Fatty Liver Disease (NAFLD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -
  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Pricing and Reimbursement Assessment
  • Retail or Manufacturer Price of Products
  • Time to Pricing and Time to Reimbursement
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts
Reasons to Buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the NAFLD market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global NAFLD market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.


  • Report Scope
  • Key Findings
  • Disease Overview
  • Epidemiology Overview
    • Epidemiology Overview: Total Prevalent Cases of NAFLD in 2022
  • Treatment Overview
    • Treatment Guidelines
  • Marketed Drugs Assessment
    • Marketed Drugs - Leading Marketed Drugs in NAFLD
    • Marketed Drug Profile: Zydus Lifesciences - Lipaglyn
  • Pricing and Reimbursement Assessment
    • Marketed Drugs - Manufacturer Price ($/mg)
  • Pipeline Drugs Assessment
    • Pipeline Drugs Overview - Mid-to-Late-Stage Pipeline Drugs in NAFLD
    • Pipeline Drugs - Overview by Development Stage
    • Pipeline Drugs - Overview by Molecule Type
    • Pipeline Drugs - Overview by Mechanism of Action
    • Pipeline Drugs - Overview by Route of Administration
    • Pipeline Drugs - Phase Transition Success Rates and Likelihood of Approval in NAFLD
    • Pipeline Drugs - Drug-Specific Phase Transition Success Rate and Likelihood of Approval in NAFLD
  • Clinical Trials Assessment
    • Clinical Trials in NAFLD - Historical Overview
    • Clinical Trials in NAFLD - Overview by Phase
    • Clinical Trials in NAFLD - Overview by Status
    • Clinical Trials in NAFLD - Overview by Phase for Ongoing and Planned Trial
    • Clinical Trials in NAFLD - Trials with a Virtual Component
    • Clinical Trials in NAFLD - Geographic Overview
    • Clinical Trials in NAFLD - Single-Country and Multinational Trials by Region
    • Clinical Trials in NAFLD - Top 20 Sponsors with Breakdown by Phase
    • Clinical Trials in NAFLD - Top 20 Sponsors with Breakdown by Status
    • Clinical Trials in NAFLD - Overview by Endpoint Status
    • Clinical Trials in NAFLD - Overview by Race and Ethnicity
    • Clinical Trials in NAFLD - Enrollment Data
    • Clinical Trials in NAFLD - Overview of Sites by Geography
    • Clinical Trials in NAFLD - Top 20 Countries for Trial Sites
    • Clinical Trials in NAFLD - Top 20 Sites Globally
    • Clinical Trials - Feasibility Analysis: Geography Overview
    • Clinical Trials - Feasibility Analysis: Benchmark Models for NAFLD
  • Deals Landscape
    • Deals Landscape - Mergers, Acquisitions, and Strategic Alliances in NAFLD by Region
    • Deals Landscape - Recent Mergers, Acquisitions, and Strategic Alliances in NAFLD
  • Commercial Assessment
    • Commercial Assessment - Key Market Players in NAFLD
  • Future Market Catalysts
    • Future Market Catalysts - Upcoming Market Catalysts in NAFLD
  • Appendix
    • Methodology
    • Methodology - Sales Forecasts
    • Methodology - Phase Transition Success Rate and Likelihood of Approval Analysis

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings